Maki Takahashi1, Taku Sato, Shoji Kishi. 1. Department of Ophthalmology, Gunma University School of Medicine, Maebashi, Japan. maki-t@wg7.so-net.ne.jp
Abstract
PURPOSE: To retrospectively study the efficacy of intravitreal bevacizumab (IVB) for exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA). METHODS: Fifteen eyes of 15 patients (mean age, 69.0 ± 11.3 years) with AMD whose VA was 0.6 or better were treated with IVB 1.25 mg/0.05 ml. The patients were followed for 12 to 29 months (mean, 17.4 ± 4.9 months). RESULTS: Best-corrected visual acuity (BCVA) ranged from 0.6 to 1.2 (mean, 0.89 ± 0.21) at baseline and was stable in 13 of 15 eyes (86.7%) when BCVA was 0.6 or better at the end of follow-up. The VA levels did not differ significantly (P = 0.42; paired t test) between baseline and the final examination. Two of the 15 eyes underwent photodynamic therapy during follow-up. The mean central retinal thickness significantly decreased from 278.4 ± 71.9 μm at baseline to 240.00 ± 58.5 μm at 3 months after the first IVB treatment (P = 0.02; Wilcoxon signed rank test). During follow-up, a mean of two injections was administered, and 47% of patients required only one injection. No adverse events developed. CONCLUSION: IVB was effective for maintaining good vision in exudative AMD in 15 eyes for at least 12 months.
PURPOSE: To retrospectively study the efficacy of intravitreal bevacizumab (IVB) for exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA). METHODS: Fifteen eyes of 15 patients (mean age, 69.0 ± 11.3 years) with AMD whose VA was 0.6 or better were treated with IVB 1.25 mg/0.05 ml. The patients were followed for 12 to 29 months (mean, 17.4 ± 4.9 months). RESULTS: Best-corrected visual acuity (BCVA) ranged from 0.6 to 1.2 (mean, 0.89 ± 0.21) at baseline and was stable in 13 of 15 eyes (86.7%) when BCVA was 0.6 or better at the end of follow-up. The VA levels did not differ significantly (P = 0.42; paired t test) between baseline and the final examination. Two of the 15 eyes underwent photodynamic therapy during follow-up. The mean central retinal thickness significantly decreased from 278.4 ± 71.9 μm at baseline to 240.00 ± 58.5 μm at 3 months after the first IVB treatment (P = 0.02; Wilcoxon signed rank test). During follow-up, a mean of two injections was administered, and 47% of patients required only one injection. No adverse events developed. CONCLUSION: IVB was effective for maintaining good vision in exudative AMD in 15 eyes for at least 12 months.
Authors: David S Boyer; Andrew N Antoszyk; Carl C Awh; Robert B Bhisitkul; Howard Shapiro; Nisha R Acharya Journal: Ophthalmology Date: 2007-02 Impact factor: 12.079
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: U Chakravarthy; A P Adamis; E T Cunningham; M Goldbaum; D R Guyer; B Katz; Manju Patel Journal: Ophthalmology Date: 2006-07-07 Impact factor: 12.079
Authors: Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer Journal: N Engl J Med Date: 2004-12-30 Impact factor: 91.245
Authors: Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili Journal: Am J Ophthalmol Date: 2003-09 Impact factor: 5.258
Authors: Ziad F Bashshur; Zeina A Haddad; Alexandre Schakal; Rola F Jaafar; Marc Saab; Baha' N Noureddin Journal: Am J Ophthalmol Date: 2007-12-11 Impact factor: 5.258
Authors: Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2009-04-18 Impact factor: 5.258
Authors: Sophie J Bakri; Melissa R Snyder; Joel M Reid; Jose S Pulido; Mohamed K Ezzat; Ravinder J Singh Journal: Ophthalmology Date: 2007-12 Impact factor: 12.079